Preclinical studies in EC models suggest that targeting FAP (e.g., with inhibitory antibodies or small molecules) or blocking IL-6 signaling can inhibit CAF activity, reduce tumor growth, and sensitize tumors to chemotherapy (62, 63). The gene discussed is FAP; the disease is neoplasm.